Pharvaris N.V. (PHVS)
NASDAQ: PHVS · Real-Time Price · USD
28.81
-1.59 (-5.23%)
May 18, 2026, 4:00 PM EDT - Market closed
Pharvaris Employees
Pharvaris had 129 employees as of December 31, 2025. The number of employees increased by 21 or 19.44% compared to the previous year.
Employees
129
Change
21
Growth
19.44%
Revenue / Employee
n/a
Profits / Employee
-$1,506,585
Market Cap
1.88B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 129 | 21 | 19.44% |
| Sep 30, 2025 | 118 | 26 | 28.26% |
| Jun 30, 2025 | 114 | 31 | 37.35% |
| Mar 31, 2025 | 119 | 36 | 43.37% |
| Dec 31, 2024 | 108 | 26 | 31.71% |
| Sep 30, 2024 | 92 | 22 | 31.43% |
| Jun 30, 2024 | 83 | 15 | 22.06% |
| Mar 31, 2024 | 83 | 17 | 25.76% |
| Dec 31, 2023 | 82 | 17 | 26.15% |
| Sep 30, 2023 | 70 | 14 | 25.00% |
| Jun 30, 2023 | 68 | 21 | 44.68% |
| Mar 31, 2023 | 66 | 25 | 60.98% |
| Dec 31, 2022 | 65 | 31 | 91.18% |
| Sep 30, 2022 | 56 | 39 | 229.41% |
| Jun 30, 2022 | 47 | 30 | 176.47% |
| Mar 31, 2022 | 41 | 27 | 192.86% |
| Dec 31, 2021 | 34 | 20 | 142.86% |
| Jun 30, 2021 | 17 | - | - |
| Mar 31, 2021 | 14 | 11 | 366.67% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sarepta Therapeutics | 835 |
| ADMA Biologics | 647 |
| Vericel | 398 |
| Intellia Therapeutics | 377 |
| Ocular Therapeutix | 325 |
| Viridian Therapeutics | 252 |
| Zymeworks | 243 |
| Stoke Therapeutics | 170 |
PHVS News
- 4 days ago - Pharvaris price target raised to $33 from $31 at BofA - TheFly
- 5 days ago - Pharvaris Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 6 days ago - Pharvaris price target lowered to $74 from $75 at Citizens - TheFly
- 6 days ago - Pharvaris reports Q1 EPS (EUR 0.59) vs. (EUR 0.85) last year - TheFly
- 6 days ago - Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 7 days ago - Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 8 days ago - Pharvaris price target raised to $31 from $30 at BofA - TheFly
- 11 days ago - Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares - GlobeNewsWire